Arvinas (NASDAQ:ARVN) Hits New 52-Week Low - Should You Sell?

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $16.43 and last traded at $16.26, with a volume of 210125 shares trading hands. The stock had previously closed at $17.77.

Wall Street Analyst Weigh In

ARVN has been the subject of several recent research reports. Wedbush reiterated an "outperform" rating and issued a $57.00 price target on shares of Arvinas in a research report on Tuesday, February 11th. Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Barclays decreased their target price on Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. Stephens started coverage on Arvinas in a research note on Monday, November 18th. They issued an "overweight" rating and a $55.00 target price on the stock. Finally, BMO Capital Markets restated an "outperform" rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $60.00.

Arvinas Stock Performance

The stock has a market capitalization of $1.19 billion, a P/E ratio of -6.23 and a beta of 1.88. The firm has a 50-day moving average price of $18.37 and a 200 day moving average price of $22.72.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the firm posted ($2.53) EPS. On average, equities analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO John G. Houston sold 31,338 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This represents a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now owns 159,121 shares of the company's stock, valued at $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arvinas

Institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in Arvinas in the 4th quarter worth approximately $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Arvinas by 0.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company's stock worth $8,311,000 after buying an additional 3,047 shares during the period. Voloridge Investment Management LLC purchased a new stake in Arvinas in the 4th quarter worth approximately $749,000. Woodline Partners LP lifted its holdings in Arvinas by 39.2% in the 4th quarter. Woodline Partners LP now owns 692,733 shares of the company's stock worth $13,280,000 after buying an additional 194,996 shares during the period. Finally, Twinbeech Capital LP purchased a new stake in Arvinas in the 4th quarter worth approximately $3,146,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.